Carnitine Supplementation and Skeletal Muscle Function

Gdansk University of Physical Education and Sport28 enrolled

Overview

Research project objectives The primary aim of the current research project is to use carnitine supplementation as the anti-inflammatory intervention for exploring the relationship between inflammation and associated with aging reduction of skeletal muscle mass. Hypothesis The carnitine supplementation modulates the blood cytokines concentration. Anti-inflammatory intervention delay the reduction of skeletal muscle mass associated with aging

Volunteers over 65 years old (n=40) are supplemented either with carnitine or placebo for 24 weeks. Before the start, in the mid-point, and after finishing the supplementation the following primary outputs variables are performed: body composition analysis (InBody720), maximal isokinetic knee extensor peak torque (Biodex System 4 Pro), blood cytokines and carnitine concentration, blood lipid profile.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Enrollment

Conditions

Sarcopenia

Interventions

carnitineDIETARY_SUPPLEMENT

1500 mg/d l-carnitine-l-tartrate

placeboDIETARY_SUPPLEMENT

isonitrogenous

Eligibility

Sex: ALLMin age: 65 YearsMax age: 70 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects with no history of gastrointestinal disorders, cardiovascular disease or hypertension. Exclusion Criteria: * Subjects having any illnesses and a history of gastrointestinal disorder, cardiovascular disease, hypertension, liver and renal disease, diabetes, cancer, alcoholism or other metabolic diseases.

Locations (1)

University of Physical Education and Sport

Gdansk, Pomeranian Voivodeship, Poland

Outcomes

Primary Outcomes

Blood Inflammatory Marker

Serum C-reactive protein concentration determined by the enzyme immunoassay method using commercially available kit (Cloud-Clone Corp., Houston, USA)

Time frame: baseline and after 24 weeks of supplementation period

Secondary Outcomes

Lipid Metabolites

Change in serum lipid metabolites: total cholesterol (TCh), HDL-cholesterol (HDL), LDL-cholesterol (LDL), triglycerides (TG) determined by standard automatic analyzer Cobas 6000 (Roche Diagnostics, Mannheim, Germany)

Time frame: baseline and after 24 weeks of supplementation period

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.